News
NRXPW
0.0026
0.00%
0.00
NRX Pharmaceuticals (NRXP) Receives a Rating Update from a Top Analyst
TipRanks · 16h ago
Weekly Report: what happened at NRXP last week (0914-0918)?
Weekly Report · 1d ago
NRX Pharmaceuticals Gains FDA Boost for Ketamine Review
TipRanks · 6d ago
NRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As Minor
NASDAQ · 6d ago
NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’
TipRanks · 09/15 19:15
FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026
Benzinga · 09/15 19:12
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
Barchart · 09/15 14:11
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Hyperfine (HYPR)
TipRanks · 09/15 10:30
NRX Pharmaceuticals Price Target Maintained With a $10.00/Share by BTIG
Dow Jones · 09/14 18:51
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target
Benzinga · 09/14 18:40
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry
Seeking Alpha · 09/14 14:26
GeNeuro Secures European Patent For GNK-301 In ALS
NASDAQ · 09/14 13:23
NRx Pharmaceuticals Enhances Investor Outreach with Updated Presentation
TipRanks · 09/14 12:33
NRx Pharma’s GeNeuro Announces Award Of European Patent Entitled Anti HERV K Envelope Antibody And Uses Thereof
Benzinga · 09/14 11:05
Weekly Report: what happened at NRXP last week (0907-0911)?
Weekly Report · 09/14 09:55
NRx Pharmaceuticals’ HOPE Therapeutics To Deploy Zeta Surgical's Newly FDA-Cleared Zeta TMS Robotic System, With Clinical Staff Now In Training Ahead Of Deployment In Florida
Benzinga · 09/11 11:04
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
Barchart · 09/11 06:00
Weekly Report: what happened at NRXP last week (0831-0904)?
Weekly Report · 09/07 09:50
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), NRX Pharmaceuticals (NRXP) and Innate Pharma (IPHA)
TipRanks · 09/02 10:30
Weekly Report: what happened at NRXP last week (0824-0828)?
Weekly Report · 08/31 09:55
More
Webull provides a variety of real-time NRXPW stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXPW
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.